دورية أكاديمية
Efficacy and one-year outcomes of Luminor® paclitaxel-coated drug-eluting balloon in the treatment of popliteal artery atherosclerosis lesions
| العنوان: | Efficacy and one-year outcomes of Luminor® paclitaxel-coated drug-eluting balloon in the treatment of popliteal artery atherosclerosis lesions |
|---|---|
| المؤلفون: | Pecoraro F., Dinoto E., Pakeliani D., Mirabella D., Ferlito F., Bajardi G. |
| المساهمون: | Pecoraro F., Dinoto E., Pakeliani D., Mirabella D., Ferlito F., Bajardi G. |
| بيانات النشر: | Elsevier Inc. |
| سنة النشر: | 2021 |
| المجموعة: | IRIS Università degli Studi di Palermo |
| مصطلحات موضوعية: | Angioplasty, Critical limb ischemia, Drug eluting balloon, Endovascular, Popliteal artery, Settore MED/22 - Chirurgia Vascolare |
| الوصف: | Purpose: Reporting outcomes with a new generation paclitaxel eluting balloon (Luminor®; iVascular, Vascular, S.L.U., Barcelona, Spain) in the popliteal district. Endovascular treatment of popliteal artery atherosclerotic disease is still debated without definitive evidences. Methods: From January to June 2019, patients’ data presenting popliteal artery atherosclerotic diseases and treated with the Luminor® (iVascular) drug eluting balloon (DEB) were prospectively collected. Critical limb ischemia (CLI) or severe claudication associated with popliteal artery stenosis >50% were the inclusion criteria. Measured outcomes were technical success, early and late results; including mortality, morbidity, symptoms recurrence, amputation, ankle-brachial index (ABI), survival, primary patency, secondary patency, freedom from restenosis. Median follow-up was 22.43 ± 4 (mean:21.58; IQR:20-24) months. Results: Of the 33 included patients, 28 (85%) were diagnosed with CLI, with a mean preoperative run-off score of 5.39 (r:0-10; SD:3) and a chronic popliteal occlusion in 21 (64%). Technical success was achieved in all cases. Perioperative mortality was observed in 1 (3%) patient and perioperative complications in 2 (6%). During the follow-up were reported 2 symptoms recurrence; a significant ABI increase (0.57; IQR:0.41-0.47 vs. 0.69; IQR:0.50-0.67; P < 0.01); 1 (3%) major and 2 (6%) minor amputations. Estimated 24 months survival, primary patency, secondary patency, and freedom from restenosis were 97%, 96.9%, 100%, and 93.8% respectively. Conclusions: In this prospective study, the use of the Luminor® (iVascular) was safe and effective in addressing atherosclerotic popliteal artery lesions. Larger studies with longer term-outcomes are required to assess the durability of this device in the popliteal artery. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/33951533; info:eu-repo/semantics/altIdentifier/wos/WOS:000726775700046; numberofpages:8; journal:ANNALS OF VASCULAR SURGERY; http://hdl.handle.net/10447/514438Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85106589642 |
| DOI: | 10.1016/j.avsg.2021.04.015 |
| الإتاحة: | https://doi.org/10.1016/j.avsg.2021.04.015Test http://hdl.handle.net/10447/514438Test |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.1C6896B3 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.avsg.2021.04.015 |
|---|